Printer Friendly

RHONE-POULENC RORER, IMMUNE RESPONSE CORPORATION ANNOUNCE A DEDICATED MANAGEMENT TEAM FOR JOINT VENTURE DEVELOPING SALK AIDS-IMMUNOTHERAPEUTIC

 COLLEGEVILLE, Pa., Nov. 20 ~PRNewswire~ -- Rhone-Poulenc Rorer (NYSE: RPR) and The Immune Response Corporation (NASDAQ: IMNR) have announced that their joint venture, Immunization Products Limited (IPL), will become an operational business unit. IPL is responsible for developing and bringing to market the AIDS Immunotherapeutic, currently in Phase II~III clinical trials.
 Dr. Elizabeth Corsi has been appointed to the position of Vice President and General Manager of IPL and will have overall responsibility for clinical development, product registration, manufacturing and marketing of IPL's products. This position will report to a new Board of Directors that will be co-chaired by James Glavin, President and CEO of The Immune Response Corporation, and Randy Thurman, Executive Vice President of RPR and President of RPR Pharmaceuticals Inc. Other personnel in Clinical Development, Biological Scale-Up and Production, Regulatory and Marketing are to be dedicated to IPL full-time.
 "We believe that a dedicated management team enables us to realize the potential of and develop the AIDS Immunotherapeutic in the most expeditious and highest quality manner," said Thurman. IMNR and RPR decided to put in place a full-time management infrastructure for Immunization Products Limited to allow for the most rapid assessment of product efficacy and, if successful, the most rapid way to make the product available to HIV-infected patients.
 Glavin added that, "Although the ultimate success of the product is undetermined at this time, we are confident that this approach best serves the interests of the patient and medical community, both companies and our respective shareholders".
 The AIDS Immunotherapeutic is based on a scientific approach first suggested by Dr. Jonas Salk, who was the developer of the first successful polio vaccine.
 The AIDS Immunotherapeutic is being tested in clinical trials as a treatment for HIV-infected patients. The product is designed to prevent, or delay, progression of HIV infection to AIDS by stimulating a patient's immune system to attack the virus. An ongoing Phase II~III efficacy trial is evaluating the effect of treatment on multiple indicators of disease progression.
 Dr. Corsi joined RPR in 1991 as Vice President, Planning and Business Development for the North American Ethicals business. Previously, she worked for Schering-Plough International and Lederle Laboratories in marketing and new product and business development and has operating experience in oncology, anti-infectives and biotechnology. Dr. Corsi has a Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science.
 The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS, and for the treatment of certain major autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
 Rhone-Poulenc Rorer Inc. is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. RPR has annual sales of $3.8 billion and research expenditures of more than $500 million.
 ~delval~
 -0- 11~20~92
 ~CONTACT: Bob Pearson of Rhone-Poulenc Rorer, 215-454-3872, or Steve Basta of Immune Response, 619-431-7080
 (RPR IMNR)


CO: Rhone-Poulenc Rorer; The Immune Response Corporation; Immunization
 Products Limited ST: Pennsylvania, California IN: MTC SU: JVN


LJ -- PH016 -- 3347 11~20~92 11:56 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 20, 1992
Words:516
Previous Article:TALKING TURKEY: HOW TO HAVE A SAFE THANKSGIVING
Next Article:SAAB 9000 QUALIFIES FOR 'LOWER-THAN-STANDARD' PREMIUMS FROM STATE FARM INSURANCE COMPANIES
Topics:


Related Articles
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMIT $18 MILLION ADDITIONAL FUNDING FOR AIDS JOINT VENTURE
THE IMMUNE RESPONSE CORP., RHONE-POULENC RORER INC. ANNOUNCE PRELIMINARY EVALUATION OF HIV THERAPEUTIC VACCINE DOSE-RANGING CLINICAL TRIAL
DOSE-RANGING STUDY SHOWS HIV IMMUNOTHERAPEUTIC STIMULATES ANTIBODY AND CELLULAR RESPONSES
DOSE-RANGING STUDY SHOWS HIV IMMUNOTHERAPEUTIC STIMULATES ANTIBODY AND CELLULAR RESPONSES
DR. JONAS SALK, ELIE WIESEL HIGHLIGHT DEDICATION OF RPR'S RESEARCH AND CORPORATE HEADQUARTERS; AIDS BENEFIT FEATURES BACHARACH, WARWICK, FLACK
SALK, WIESEL HIGHLIGHT DEDICATION OF HEADQUARTERS FOR RHONE-POULENC RORER; BACHARACH, WARWICK, FLACK AND BOOSLER HEADLINE AIDS BENEFIT
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMENCE ARBITRATION
THE IMMUNE RESPONSE CORPORATION REGAINS ALL RIGHTS TO HIV IMMUNOTHERAPEUTIC FROM RHONE-POULENC RORER INC.
THE IMMUNE RESPONSE CORPORATION ANNOUNCES FIRST QUARTER 1995 FINANCIAL RESULTS
Rhone-Poulenc Rorer Propharm Announces Measures to Improve Industrial Operations Competitiveness

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters